Ubushakashatsi bwamurikiwe mu nama y’ihuriro ry’abaganga b’inzobere mu kuvura kanseri bo muri Leta Zunze Ubumwe za Amerika (ASCO) ku wa 1 Kamena 2025, bwagaragaje ko umuti mushya wa Camizestrant ukorwa n’uruganda AstraZeneca ushobora guhagarika gukura kwa kanseri y’ibere.

Ubu bushakashatsi bwagaragaje ko uyu muti ushobora kwifashishwa nyuma y’ibizamini bifatwa hakoreshejwe amaraso bizwi nka ‘liquid biopsy’ bigaragaza niba imiti isanzwe ntacyo igifasha umubiri.

Isuzuma ryakorewe ku bagore 3.256 bafite kanseri y’ibere, bigaragara ko imiti isanzwe ntacyo ikimarira abagera kuri 315.

Bamwe muri aba barwayi bahawe umuti wa Camizestrant ndetse n’undi uri mu itsinda rya CDK5/6, abandi bakomeza imiti isanzwe hagamijwe kureba itandukaniro.

Mu cyiciro cya CDK5/6 harimo imiti myinshi isanzwe ihagarika imisemburo ifasha kanseri gukura nka Novartis, Kisqali, Ibrance ndetse na Verzenio.

Byagaragaye ko abahawe Camizestrant na CDK5/6 bamaze amezi 16 kanseri y’ibere itagikura, mu gihe ku bakomeje kunywa imiti isanzwe bo yakomeje gukura.

Abashakashatsi bemeje ko hari amahirwe ya 56% y’uko kanseri y’ibere ihagarika gukura mu gihe uyirwaye yanywa umuti wa Camizestrant ndetse n’undi umwe mu miti ya CDK5/6, ndetse bikaba byanagabanya ibyago by’urupfu.

Inzobere mu buvuzi bwa kanseri, Dr. Eleonora Teplinsky, yatangaje ko ubu bushakashatsi bushobora guhindura uburyo busanzwe bw’ubuvuzi bwa kanseri y’ibere.

Dr. Teplinsky yasobanuye ko nubwo umuti wa Camizestrant utaremezwa n’ikigo cya Amerika gishinzwe ubugenzuzi bw’imiti n’ibiribwa, FDA, kugira ngo ukoreshwe mu kuvura kanseri y’ibere, hari amahirwe ko kizawemeza mu gihe kiri imbere.